CenterBook Partners LP Raises Stock Position in Xeris Biopharma Holdings, Inc. $XERS

CenterBook Partners LP raised its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 99.3% during the fourth quarter, Holdings Channel reports. The firm owned 1,391,590 shares of the company’s stock after buying an additional 693,386 shares during the quarter. CenterBook Partners LP’s holdings in Xeris Biopharma were worth $10,924,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. AlphaQuest LLC purchased a new position in Xeris Biopharma during the 3rd quarter valued at $35,000. Northwestern Mutual Wealth Management Co. increased its position in Xeris Biopharma by 179.3% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock valued at $63,000 after purchasing an additional 5,000 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Xeris Biopharma by 29.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after purchasing an additional 1,820 shares during the period. Kingsview Wealth Management LLC purchased a new position in Xeris Biopharma during the 4th quarter valued at $78,000. Finally, Mercer Global Advisors Inc. ADV purchased a new position in Xeris Biopharma during the 3rd quarter valued at $85,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Price Performance

NASDAQ:XERS opened at $6.18 on Monday. The firm’s 50-day moving average price is $6.10 and its 200-day moving average price is $6.59. The company has a market capitalization of $1.07 billion, a PE ratio of 103.00 and a beta of 0.78. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50. Xeris Biopharma Holdings, Inc. has a 1-year low of $4.30 and a 1-year high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. The firm had revenue of $83.13 million for the quarter, compared to the consensus estimate of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. On average, equities analysts predict that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current fiscal year.

Insider Buying and Selling

In other Xeris Biopharma news, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $6.09, for a total transaction of $97,440.00. Following the transaction, the director owned 126,500 shares in the company, valued at approximately $770,385. This represents a 11.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Marla Persky sold 15,500 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $5.90, for a total transaction of $91,450.00. Following the sale, the director directly owned 126,500 shares of the company’s stock, valued at $746,350. The trade was a 10.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 127,335 shares of company stock worth $766,733 over the last quarter. 4.35% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on XERS shares. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Xeris Biopharma in a research report on Monday, March 2nd. Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Xeris Biopharma has an average rating of “Hold” and a consensus target price of $10.80.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.